Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

autologous UV-oHSV2-activated peripheral blood mononuclear cells

A preparation of autologous peripheral blood mononuclear cells (PBMCs) activated ex vivo by ultraviolet-inactivated oncolytic herpes simplex virus type 2 (UV-oHSV2), with potential immunomodulating and antineoplastic activities. Upon reintroduction of the autologous UV-oHSV2-activated PBMCs into the patient, the activated immune cells kill tumor cells. Ex vivo UV-oHSV2 treatment induces natural killer (NK) cell proliferation and the secretion of interferon-gamma (IFNg). This leads to immune-mediated tumor cell death and the inhibition of tumor cell proliferation.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:autologous ultraviolet inactivated oncolytic herpes simplex virus type 2-activated peripheral blood mononuclear cells
autologous UV-oHSV2-activated PBMCs
autologous VAK immune cells
autologous virus-activated killer immune cells
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search